This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Comparison of a Novel Non-diffractive Extended Depth of Focus Intraocular Lens (IOL) and a Trifocal IOL

Sponsored by Baskent University Ankara Hospital

About this trial

Last updated 2 years ago

Study ID

Vivity Panoptix

Status

Completed

Type

Observational

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 4 years ago

What is this trial about?

The purpose of this study is to compare visual performance and quality of life (QOL) following bilateral implantation of a novel non-diffractive extended depth-of-focus (EDOF) intraocular lens (IOL) (AcrySof® IQ Vivity, Alcon, TX, USA) and a trifocal IOL (Acrysof® IQ PanOptix, Alcon, Fort Worth, TX) in a prospective comparative interventional case series.

What are the participation requirements?

Yes

Inclusion Criteria

- Cataract patients scheduled for surgery who are interested in spectacle independence.

- Bilateral cataract with plan of bilateral sequential cataract surgery.

- Adult patients older than 18 years of age

- Normal cognitive function, able to understand advantages and disadvantages associated with different types of IOLs.

No

Exclusion Criteria

- Ocular diseases other than cataract including irregular astigmatism, diabetic retinopathy, age-related macular degeneration or any other retinal diseases, severe dry eye, glaucoma, amblyopia, uveitis, pseudoexfoliation syndrome, abnormal pupillary function, history of intraocular or corneal surgery, congenital eye abnormalities, or eye trauma.

- Patients with high myopia with axial length (AL) ≥ 26,5 mm and high hyperopia (AL ≤ 21.5 mm)

- Lifestyle and work-related factors requiring sharp near or distance vision

- Patients with unrealistic visual expectations.

Locations

Location

Status